Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The goal of this research is to assess the percentage of non-responders to ≥ 2 NSAIDs
candidates a biological therapy that could adequately respond to treatment with etoricoxib
This study confirm the result of a previous study in a wider similar population. Basing on
previous results, the response rate will be assessed by ASASBIO criteria. The efficacy of the
treatment with etoricoxib 90 mg will be assessed at week 4 in a population of patients with
AS who didn't respond adequately to a previous therapy with ≥ 2 NSAIDs.
Those patients that, based on the ASABIO criteria, achieved a sufficient clinical response
will be followed until week 24 to asses the maintenance of the study drug effects.